



ADVISORY

No. 247

May 23, 2023

Brand vs Generic (DAW6) Changes to Maryland Medicaid's Preferred Drug List (PDL)

Effective June 6, 2023:

The Office of Pharmacy Services (OPS) wants to alert you that effective June 6, 2023:

- **The following insulin Brands will no longer be preferred** over its respective generic equivalent.

Humalog Jr Kwikpens 100unit/ml	Novolog mix vials 70/30
Humalog Mix Kwikpens 75/25	Relion Novolog mix vial 70/30
Humalog vials 100 unit/ml	Novolog pens 100 unit/ml
Humalog Kwikpens 100 unit/ml	Relion Novolog Pen 100unit/ml
Novolog cartridges/penfiles	Novolog vials 100 unit/ml
Novolog mix pen 70/30	Relion Novolog vial 100 unit/ml
Relion Novolog mix pen 70/30	Lantus Solostar 100 unit/ml

Claims for the brand will now adjudicate only if there is a prior authorization based on an approved Maryland Department of Health (MDH) MedWatch form:

<https://health.maryland.gov/mmcp/pap/docs/PA%20Forms/Maryland%20Medwatch%20Form.pdf>

If any problems are encountered during the online claim adjudication, contact Conduent 24-hour Help Desk at 800-932-3918 for additional system overrides related to the use of the correct DAW code (for example, if there is other primary insurance).

Please refer to our website for the Preferred Drug List (PDL) and Brand Preferred over Generics List:

<https://health.maryland.gov/mmcp/pap/pages/Preferred-Drug-List.aspx>

All Advisories are available online on MDH's web link at:

<https://health.maryland.gov/mmcp/pap/Pages/Provider-Advisories.aspx>

In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Maryland Department of Health (MDH), **Office of Pharmacy Services (OPS)** has developed the **Maryland Medicaid Pharmacy Program Advisory**.

To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, CARE, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations.

It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via MDH, please contact the OPS representative at 410-767-1455.